bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) and Labcorp (NYSE:LH – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.
Valuation and Earnings
This table compares bioAffinity Technologies and Labcorp”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| bioAffinity Technologies | $6.16 million | 0.39 | -$14.91 million | ($109.45) | -0.04 |
| Labcorp | $13.95 billion | 1.89 | $876.50 million | $12.09 | 26.86 |
Labcorp has higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 95.9% of Labcorp shares are held by institutional investors. 2.7% of bioAffinity Technologies shares are held by insiders. Comparatively, 0.8% of Labcorp shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk & Volatility
bioAffinity Technologies has a beta of -1.25, suggesting that its share price is 225% less volatile than the S&P 500. Comparatively, Labcorp has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.
Profitability
This table compares bioAffinity Technologies and Labcorp’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| bioAffinity Technologies | -257.30% | -220.52% | -136.76% |
| Labcorp | 6.99% | 16.74% | 7.81% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for bioAffinity Technologies and Labcorp, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| bioAffinity Technologies | 1 | 0 | 0 | 0 | 1.00 |
| Labcorp | 0 | 3 | 9 | 0 | 2.75 |
Labcorp has a consensus target price of $337.73, suggesting a potential upside of 4.01%. Given Labcorp’s stronger consensus rating and higher possible upside, analysts plainly believe Labcorp is more favorable than bioAffinity Technologies.
Summary
Labcorp beats bioAffinity Technologies on 12 of the 13 factors compared between the two stocks.
About bioAffinity Technologies
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
About Labcorp
Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
